Given the facts that SIRT4 expression is often downregulated in most malignant cancers 16-18 and correlated with a poor clinical outcome in ESCC 19, and SIRT4 is among the 428 genes mentioned above with high matching score (Fig. 4A), we focused on validation of SIRT4 in our subsequent experiments. This evidence concerns the gene SIRT4 and cancer.